Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EFFECTS OF SEROTONIN REUPTAKE INHIBITORS ON AGGRESSIVE-BEHAVIOR IN PSYCHIATRICALLY HOSPITALIZED ADOLESCENTS - RESULTS OF AN OPEN TRIAL
Autore:
CONSTANTINO JN; LIBERMAN M; KINCAID M;
Indirizzi:
WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,4940 CHILDRENS PL ST LOUIS MO 63110 WASHINGTON UNIV,SCH MED,DEPT PEDIAT ST LOUIS MO 63110 HAWTHORN CHILDRENS PSYCHIAT HOSP ST LOUIS MO 00000
Titolo Testata:
Journal of child and adolescent psychopharmacology
fascicolo: 1, volume: 7, anno: 1997,
pagine: 31 - 44
SICI:
1044-5463(1997)7:1<31:EOSRIO>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
CEREBROSPINAL-FLUID MONOAMINE; VIOLENT OFFENDERS; FIRE SETTERS; PERSONALITY; FLUOXETINE; SERTRALINE; CSF; METABOLITES; VOLUNTEERS; STABILITY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
45
Recensione:
Indirizzi per estratti:
Citazione:
J.N. Constantino et al., "EFFECTS OF SEROTONIN REUPTAKE INHIBITORS ON AGGRESSIVE-BEHAVIOR IN PSYCHIATRICALLY HOSPITALIZED ADOLESCENTS - RESULTS OF AN OPEN TRIAL", Journal of child and adolescent psychopharmacology, 7(1), 1997, pp. 31-44

Abstract

Low concentations of the neurotransmitter serotonin and its 5-hydroxyindoleacetic acid metabolite in the central nervous system have been associated with increased aggressive behavior in animals and humans. Controlled clinical trials of serotonin agonists in depressed adults have suggested that aggressive behavior is less likely during treatment with these medications than with placebo, but there have been no previous studies of selective serotonin reuptake inhibitors (SSRIs) and aggression in children. We prospectively followed the course of aggressivebehavior in 19 psychiatrically hospitalized adolescents (not selectedfor aggressiveness) who received open clinical trials of fluoxetine, paroxetine, or sertraline. The patients received standard doses (equivalent to fluoxetine 10-40 mg daily) for a minimum of 5 weeks. The starting dose was 15 +/- 5 mg, and dosages were raised at a mean rate of 5mg every 4 days up to a mean dose of 25 +/- 10 mg daily. Results fromtrials of the three SSRIs were clustered because the sample sizes were not sufficient for separate analyses. Overall, there were no statistically meaningful improvements in the level of aggressive behavior, asmeasured on a modified version of the Overt Aggression Scale, over the course of these patients' SSRI trials. Symptoms of physical aggression toward others or self were manifest in 12 of the 19 patients while on SSRIs. Of the 19 patients, 13 were assessed both on and off SSRIs: verbal aggression (p = 0.04), physical aggression toward objects (p = 0.05), and physical aggression toward self (p < 0.02) occurred significantly more frequently on SSRIs than off; no increase was observed in physical aggression toward others. Patients with the highest baseline aggressivity scores did not show greater improvement during SSRI treatment. Further research is warranted, particularly to explore whether SSRIs may have therapeutic effects on aggression at higher (or lower) doses than were administered in this open trial.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 20:53:53